

TMHMM posterior probabilities for Sequence
Probability
1.2
1
0.8
0.6
0.4
0.2
0
0
100
200
300
400
500
A

FIG. 1




FIG. 1 continued

A.



ECR1
ERC2
N-Linked Glycosylation
MS Identified Cell Surface Peptides
Disordered Region
1
2
3
4
5
6
Cytoplasmic

FIG. 2

B.




FIG. 2 continued





Sequence analysis for CLPTH1L
Epitope value
Epitope selected
Hydrophilic
Hydrophobic
Signal Peptide
Transmembrane
focus region
178
150.2
122.4
94.6
66.8
39
11.2
-16.6
-44.4
-72.2
-100
5
58
111
164
217
270
323
376
429
482
535

FIG. 3


A
Surface
Whole Cell
CLPTM1L
EGFR
Cyclin D1
B
Non Permeablized A549 Cells
DAPI
CLPTM1L
DAPI
Isotype CONTROL
C
IB: CLPTM1L
6-1
10-2
10-3
62 kDa
D

A



Summary:

	Mean	SEM	N	t-test
normal	0	0	16	
tumor	1.456784	0.124848	31	p<0.05

Intensity scoring - 0=negative 1=weak 2=moderate 3=strong

FIG. 5

B Overall Survival by cipt tertile




FIG. 5 continued




FIG. 5 continued

A




FIG. 6

B




FIG. 6 continued

C




FIG. 6 continued

D

Monoclonal antibody 10-2 treatment of PDAC cells




FIG. 6 continued



Beas2B(NNK)
Beas2B(NNK)-EGF
Colonies per Well
0
10
20
30
40
50
60
70
80
90
100
Control
anti-CLP
Beas2B
Beas2B-EGF
Colonies per Well
0
5
10
15
20
25
30
35
40
45
Control
anti-CLP

FIG. 7




FIG. 7 continued




FIG. 8

B.




FIG. 8 continued

A.



250
200
150
100
50
0
Mean Tumor Volume (sq.mm)
Control
(6-1)
(10-2)
(10-3)
pAb
Average
*
**
**
*

FIG. 9

B.




FIG. 9 continued

Characterization of in-vitro anti-tumor effects of monoclonal anti-CLPTM1L antibodies

mAb	Targets Both Isoforms	IF Staining Intensity	Punctate Surface Staining	pAkt Inhibition		Bcl-xL Inhibition		CDDP Sensitization		Tumor Spheroid Growth
		A549	A549	A549	H838	A549	H838	A549	H838	H838
6-1	-	+++	-	++	+/-	+	-	+	+	-
6-2	-	+	-	+	+/-	+	-	-	+/-	-
7-1	-	++	-	+/-	-	+/-	-	-	-	-
7-2	-	+	-	-	-	+/-	-	-	+/-	-
8	+	++	+	+/-	-	-	-	+	+	-
9-1	+	++	+	+	-	+	-	+/-	+	-
9-2	+	+	+	-	+/-	+/-	+/-	+/-	-	-
10-1	+	++	+	+	+/-	-	+/-	-	+/-	+/-
10-2	+	++	+	++	+	+	+	+/-	+/-	+
10-3	+	+++	+	++	+	+	+	+/-	+/-	+

FIG. 10